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Stable interconnection to neurons in vivo over long time-periods is critical for the success of future
advanced neuroelectronic applications. The inevitable foreign body reaction towards implanted mate-
rials challenges the stability and an active intervention strategy would be desirable to treat inﬂammation
locally. Here, we investigate whether controlled release of the anti-inﬂammatory drug Dexamethasone
from ﬂexible neural microelectrodes in the rat hippocampus has an impact on probe-tissue integration
over 12 weeks of implantation. The drug was stored in a conducting polymer coating (PEDOT/Dex),
selectively deposited on the electrode sites of neural probes, and released on weekly basis by applying a
cyclic voltammetry signal in three electrode conﬁguration in fully awake animals. Dex-functionalized
probes provided stable recordings and impedance characteristics over the entire chronic study. Histo-
logical evaluation after 12 weeks of implantation revealed an overall low degree of inﬂammation around
all ﬂexible probes whereas electrodes exposed to active drug release protocols did have neurons closer to
the electrode sites compared to controls. The combination of ﬂexible probe technology with anti-
inﬂammatory coatings accordingly offers a promising approach for enabling long-term stable neural
interfaces.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The development of implantable microelectrodes has revolu-
tionized the ﬁeld of biomedical applications by enabling bi-
directional communication with neural tissue at high resolution.
In particular penetrating probes, extending deep into neural
structures, allowed substantial progress in the understanding of
neuronal pathways and networks [1e4]. They further promoted
therapeutic and diagnostic applications like deep brain stimulation
(DBS) for treating symptoms of Parkinson’s disease or severe psy-
chiatric disorders [5,6]. In addition, brain machine interfaces (BMIs)
and associated neuro-prosthetic devices rely on signals recorded
from or delivered across such neural electrodes [7e9].
In chronic recordings of electrophysiological signals with
penetrating probes it has however been observed that signalsstems Engineering (IMTEK),
110 Freiburg, Germany.
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Ltd. This is an open access article uattenuate or disappear after only few weeks post implantation
[10,11]. This effect is attributed to a foreign body reaction taking
place around any object inserted into tissue. In consequence to the
insertion trauma along with the disruption of the blood brain
barrier as well as the presence of the probe itself, a complex cascade
of immune reactions is triggered [12]. These processes can be
summarized into two phases relevant for neural probes [11]: An
increased concentration of activated microglial cells around the
probe, identiﬁed by the ED-1 antibody, is characteristic for the
acute inﬂammation phase immediately following the implantation
[13]. With progressing time, this acute inﬂammation develops into
a chronic state which is deﬁned by a dense astrocytic scar tissue
(identiﬁed by glial ﬁbrillary acidic protein (GFAP)) encapsulating
the probe [11,14,15]. Alongwith the accumulation of scar tissue over
several weeks, a reduction in the number of neurons in close
proximity to the implanted probe has further been observedwithin
a radius of ca. 100 mm around the probe [14,16]. It is to date still
unknown whether this loss is caused by the migration of neurons
away from the implanted probe, whether neurons are repellednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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degenerate by other means in this process. This chronic inﬂam-
mation state and the loss of close-by neurons impairs the long-term
functionality of microelectrodes and ultimately leads to reduction
of recorded signal quality. Under these conditions, electrical stim-
ulation parameters need to be continuously adjusted to retain
efﬁcient tissue activation over time [10,11,17,18]. For silicon based
implants, chronic inﬂammatory reactions have been found in tissue
extending as far as 300 mm [19] or 10 mm [20] away from the probe
surface beyond 16 weeks of implantation in the rat or macaque
cortex, respectively. In contrast, stab-wounds did not show any
persistent inﬂammation, demonstrating that the probe itself rather
than the implantation trauma leads to the chronic inﬂammation
state [19]. Variations in probe geometries and implantation tech-
niques were further not found to result in improved chronic tissue
response [21e23].
In order to attenuate the immune reactions towards implanted
probes, ﬂexible substrates were introduced aiming at minimizing
the mechanical mismatch between the tissue and the probe
[24,25].With this approach, micro-motion associated inﬂammation
was addressed which occurs in consequence to microscopic
movements of stiff implants inside soft tissue [11]. Flexible sub-
strate materials, such as polyimide (PI) with a Young’s Modulus of
~9 GPa, were reported to provide lower tissue reactions when
compared to scar formation described in the literature for stiff
silicon implants (Young’s modulus of ~180 GPa) [26e28]. Precise
insertion of such ﬂexible probes into the cortex however is
demanding and requires complex insertion techniques, posing
limitations to this approach [29e31]. Attaching biomolecules to the
surface of stiff silicon implants has further been shown to reduce
neuronal loss in the close vicinity to the probe [32].
Aiming at modifying the biological side rather than the probe
itself, delivery of anti-inﬂammatory drugs has been described as
strategy for attenuating chronic immune reactions and was in
particular suggested to slow down neurodegeneration [19]. This
technology can be used independent of the probe geometry or type
and offers the possibility to directly inﬂuence the cellular reactions
in the close vicinity to the implanted probe. Dexamethasone (Dex)
is the most prominent corticosteroid drug described for inﬂam-
mation attenuation. Several studies demonstrated reduced
inﬂammation when Dex was released from passively eluting sub-
strates (e.g. PLGA microspheres) implanted subcutaneously
[33e36] or in the central nervous system [37e42] for times be-
tween 6 h and 28 days. The pharmacological efﬁcacy of the drug
was not inﬂuenced by the storage and subsequent release [36,38]. It
has nevertheless been observed that the chronic immune response
could not be affected by such passive eluting systems for implan-
tation times beyond 30 days [39,43e45]. This observation dem-
onstrates that pharmacological modulation of the tissue response
during the acute inﬂammation phase is not sufﬁcient but rather
sustained delivery technologies with active control over release are
required to address the chronic immune reaction.
Conducting polymers (CPs) like poly(3,4-
ethylenedioxythiophene) (PEDOT) have been described as prom-
ising material for such active release technology in biomedical
applications. Introduced as electrode coatings with low impedance
and high charge injection capacity for neural probes [46e49], CPs
further provide the possibility to incorporate, and thus store, ionic
substances such as drugs in their bulk. Controlled release of stored
drugs can subsequently be achieved by applying an electrical signal
to the CP which enables high temporal control over drug expulsion
[50e52]. Proof of concept for actively triggered release of Dex from
such systems has been demonstrated in vitro from large substrates
(0.1e4 cm2) and for comparably short time frames (minutes to
hours) [53e59]. Active drug release in vitro over longer time frames(up to four weeks) has been reported by us in a previous study [60]
suggesting that chronic immune response modulation with such
release technology is generally feasible. Chronic in vivo studies
employing micro-scale probes with active drug delivery function-
ality tested over several months have however not been reported in
literature so far. It is therefore still unknown whether such CP
release systems provide an efﬁcient means for attenuating the
chronic immune response to implanted neural probes at time
frames and in dimensions more relevant for clinical applications.
We here target this question by combining the beneﬁcial
properties of a ﬂexible neural probe with the active drug delivery
properties of CPs. The impact of this probe technology on the
chronic immune response is evaluated over 12 weeks in vivo
employing weekly triggered active release of Dex from PEDOT/Dex
coated electrode sites in the rat brain. Electrophysiological, elec-
trochemical and immunohistochemical data are collected from
functionalized probes and non-functionalized controls implanted
bilaterally in the hippocampus of 12 rats. Thereby techniques
promoting stable long-term adhesion for CP coatings as well as
strategies for enabling precise insertion of polyimide ﬂex-probes
are employed.
2. Materials and methods
2.1. Basic electrode fabrication
Neural probes for in vitro and in vivomeasurements were based
on ﬂexible polyimide substrates with a platinum metallization
embedded between two polyimide layers, fabricated according to
the process described by Stieglitz et al. [24]. In brief, a 5 mm thin
polyimide layer was deposited on a carrier wafer. For adhesion
promotion, 50 nm of Silicon Carbide (SiC) were deposited on the
polyimide in a chemical vapour deposition process [61]. Subse-
quently, 100 nm of platinum and 400 nm IrOx were sputtered on
the polymer substrate and photo-lithographically patterned to
deﬁne the electrode sites. IrOx thereby served as adhesion pro-
moter for the subsequent PEDOT coatings [62]. Finally, a second
polyimide layer of 5 mm thickness was deposited as insulation layer
and selectively opened via reactive ion etching to create the elec-
trode sites as well as the contact pads. The resulting ﬂex-probes
were 10 mm thin with a shaft of 380 mm width and 15 mm in
length. The probes featured 16 individual electrode contacts with
12 electrode sites of 15  15 mm2 and four electrode sites of
50 50 mm2 according to the layout in Fig.1a. A large ring-aperture,
reinforced with a circular platinum electrode, was integrated at the
tip of each electrode (Fig. 1a) to serve as guidance for an insertion
tool during implantation. The distal end of the probe was designed
to ﬁt into a conventional ZIF-connector.
2.2. Deposition of PEDOT/Dex coatings
Aiming at attenuating the foreign body response, the four large
electrodes in the midline of the probe shaft were selected for car-
rying an anti-inﬂammatory coating. For being able to actively
modulate the drug expulsion, this coating was based on the con-
ducting polymer PEDOT. The corticosteroid Dexamethasone 21-
phosphate disodium salt (Dex) was incorporated into the PEDOT
during the polymerization process and was thus stored in a
conﬁned area on the probe. The coating was realized by galvano-
static electropolymerization using an Autolab potentiostat
(PGSTAT128N, Metrohm, Filderstadt, Germany) in a three electrode
conﬁguration with a stainless steel counter electrode (2 cm2) and
an Ag/AgCl reference electrode. An aqueous solution of 0.01 M
EDOT and 0.01 M Dex was used as electrolyte and the deposition
was carried out at a current density of 800 mA/cm2 with a target
Fig. 1. a) Microscope image of a polyimide neural probe with 4 PEDOT/Dex coated
electrode sites shown in blue. Probe insertion is performed according to the process
shown in b) with an optical ﬁbre as guiding tool. The ﬁnal placement of the electrodes
can be seen in c). Both the passive probe (control) and the active probe (functionalized)
are ﬁxated to the skull. The connection of the active probe to the recording/stimulation
equipment is achieved via a connector placed on the head of the animal (d). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
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contact sites were subjected to an electrochemical preconditioning
step using cyclic voltammetry (CV) scans (0.6 Ve0.9 V at 0.1 V/s)
in phosphate buffered saline (PBS, 0.01 M) until a stable redox-
behaviour was observed (typically after 25 scans). Subsequent to
the polymerization, all probes were rinsed with Milli-Q water and
stored in sterile PBS overnight allowing elution of loosely adsorbed
EDOT and Dex on the probe surface before the shafts were
implanted.
Besides the anti-inﬂammatory PEDOT/Dex coatings, also non-
functionalized CP coatings were realized on selected probes to
serve as controls. The cleaning and deposition parameters were
identical to the previously described process, however, sodium
polystyrenesulphonate (NaPSS, 5 mg/ml) was used as counter ion
instead of Dex. The resulting coatings are hence denoted as PEDOT/
PSS. In total 30 probes were prepared, whereas 24 were implanted
according to Table 1 and the remaining 6 were subjected to in vitro
measurements.2.3. Implantation procedure of Dex-coated probes
All animal experiments conducted in this study were performed
with approval from the locally responsible Animal Welfare Com-
mittee with the Regierungspr€asidium Freiburg in accordance with
the guidelines of the European Union Directive 2010/63/UE (permit
G13/51). The animal model chosen consisted of twelve adult female
Sprague Dawley rats (Charles River, Germany), weighing
280e320 g (avg. 314 g) andmaximal efforts weremade tominimize
the number of animals used with respect to statistical constraints.
Prior to surgery, all rats underwent several weeks of handling in
order to familiarize them with the experimenter and subsequently
enable drug release in fully awake and freely moving animals. TheTable 1
List of all 12 animals with the implanted probes in the right (R) or left (L) hemisphere.
1 2 3 4
PEDOT/Dex active (CV-stimulation) R R R R
PEDOT/Dex passive (no stimulation)
PEDOT/PSS active (CV- stimulation)
PEDOT/PSS passive (no stimulation) L L L L
IrOx passive (no stimulation)animals were initially sedated with Isoﬂurane and subsequently
anesthetized with Ketamine (100 mg/kg) and Xylazine (3 mg/kg).
Disinfectant (Softasept) was applied to the scalp and the surgical
ﬁeld was prepared by shaving the area using small animal shears.
Protective ointment (Bepanthen™ eye and nose ointment) was
applied to the eyes to prevent drying and to provide a physical
barrier during surgery. Anesthetized and shaved rats were placed in
a stereotactic frame (Kopf Instruments, Tujunga, USA) with atrau-
matic ear bars (tooth bar ¼ 0.0). After mid-line incision, the skull
was exposed and a total of 8 holes with 0.9 mm diameter were
carefully drilled into the skull whereas 6 holes were located in a
circular pattern laterally on the skull. Stainless steel screws were
inserted into the 6 lateral holes so that the screw heads extended a
few mm over the bone. These screws were later used as anchor
points for additional stabilization of the dental cement which was
used to ﬁx the connector to the skull. The two holes for the actual
electrodes were drilled at 3.6mmposterior and 2.5mm lateral with
respect to bregma. The dura was removed manually using a bent
syringe-needle (27G). Each animal received two probes targeting
the CA1 region of the hippocampus (DV: 2.2 mm from dura
mater). The probe in the left hemisphere always served as material-
reference and the probe in the right hemisphere was used for the
actual recording/stimulation experiments. A list of the 12 animals
with the corresponding probes can be found in Table 1. Insertion of
the probes was facilitated with a glass ﬁbre (125 mm diameter
without cladding) that was threaded through the ring structure on
the tip of the probes and thereby enabled straight insertion of the
ﬂexible substrate as indicated in Fig. 1b. This process was modiﬁed
from the procedure described by Richter et al. and Loefﬂer et al.
[31,63]. After implantation, control probes were ﬁxed to the skull by
super glue (cyanoacrylate) and the connection site of the probes
was trimmed (see Fig. 1c). Active probes were ﬁxed to the skull in
an equal manner, but the connection sites of these probes were
inserted into a custommade printed circuit board (PCB) which was
then sealed with UV-curable adhesive. The PCB was ﬁxated on the
skull using 2 component dental cement (Palapress, Heraeus Hold-
ing GmbH, Germany) so that one end of the PCB, carrying an 18-pin
Omnetics connector (A79040-001, Omnetics Connector Corpora-
tion, USA), remained accessible for connecting the animal to the
external recording or stimulation equipment (Fig. 1d). The skinwas
sutured around the dental cement and the animals were allowed to
recover for one week under prophylactic daily administration of
Caprofen (Carprieve, Norbrook, UK, 4 mg kg1 s.c.) pain reliever.
Animal weights were further regularly measured as indicator for
their overall health status during the 12 weeks experimental time.
Continuous gain in weight could be observed for all animals,
demonstrating good health conditions so that no animal had to be
excluded from the experiments.2.4. Neural recordings
During the ﬁrst week after surgery, animals were allowed to
recover and no drug elution or recordings were performed during
this time. In the subsequent weeks, awake and freely moving5 6 7 8 9 10 11 12
R R R R
R R R R
L L
L L L L L L
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cordings were performed with an RZ5 multichannel recording
system (Tucker-Davis Technologies, Alachua, USA) and neural ac-
tivity was simultaneously recorded from all 16 electrode sites on
the probe over 120 s at a sampling rate of 40 kHz. Local Field Po-
tentials (LFPs) were extracted from these data by low pass-ﬁltering
(300 Hz) directly during data acquisition. Further data ﬁltering was
performed ofﬂine after analog-digital conversion using the pro-
gram NeuroExplorer4 (Nex Technologies, Madison, USA) where a
low pass ﬁlter (40 Hz cutoff frequency, 10th order lowpass) was
used to eliminate the 50 Hz noise.2.5. Impedance spectroscopy measurements
Following neural recordings, the animals were connected to a
potentiostat (PGSTAT 204, Metrohm, Filderstadt, Germany) for
in vivo impedancemeasurements. Here only the four PEDOT-coated
electrode sites were used on each probe and individually connected
as working electrode in a three electrode conﬁguration. The plat-
inum ring structure on the probe-tip was used as counter electrode
and a small IrOx electrode located in the centre of the probe served
as reference electrode (Fig. 1a), forming an electrochemical cell
directly on the probe. Suitability of IrOx as (pseudo) reference
material in biomedical applications has previously been described
by Shinwari et al. [64] and Yang et al. [65]. Care was taken to ensure
a ﬁrm connection and the open circuit potential (OCP) was
observed for at least 10 s to conﬁrm stable electrode conﬁguration.
The impedance spectrum was then recorded between 1 Hz and
10 kHz using sinusoidal excitation signals with an amplitude of
10 mV. This measurement was done for all animals, regardless of
the polymer coating type.
Impedance measurements from in vitro probes were performed
in the same electrode conﬁguration with identical settings in
0.01 M PBS.2.6. On-demand drug release in vivo
Controlled release of Dex for attenuation of the foreign body
response to the implant was performed on a weekly basis (starting
at week 2 post op in vivo). Drug elution was triggered subsequently
to the impedance measurements in the fully awake and mobile
animal using the same electrode conﬁguration. A CV-signal was
successively applied to each of the four coated electrode spots per
probe and drug release was triggered by three CV scans
between 0.6 V and 0.15 V (vs. the IrOx reference) at a scan speed
of 0.1 V/s. The potentiostat was programmedwith both voltage and
current limitations (0.65 V, 0.2 V and 10 mA) in order to keep the
stimulation sub-threshold for neuronal effects and to avoid un-
predictable current ﬂow. This ensured animal safety at any time
during the drug release process. Over the 12 weeks, these limits
were never reached or exceeded. In addition, no behavioural
response was ever observed during the 45 s of CV-stimulation,
conﬁrming sub-threshold stimulation.
Identical CV-sweeps were applied to the group of animals
implanted with active PEDOT/PSS probes. In this case no release of
the PSS can be expected as consequence to the immobilized bulky
PSS anion. These animals serve as control group to evaluate the
effect of the stimulation signal on the immune response intensity in
contrast to the release of Dex from the PEDOT/Dex probes. CV
curves were further used to determine the CSC by integrating the
area under the curves. The CSC thereby serves in parallel as mea-
sure for the electrode status, which has previously also been
described by Alba et al. in vivo [66] and by Boehler et al. [62] for
long-term monitoring of electrode properties in vitro.2.7. Histology and image analysis
Following 12 weeks of implantation, all animals were put in
deep anaesthesia using 300 mg/kg Ketamine and 9 mg/kg Xylazine
i.p. and subsequently trans-cardially perfused by paraformaldehyde
and PBS. All ﬂex-probes, except for one which was explanted for
SEM imaging, remained in the tissue and care was taken while
removing the connector and extracting the brain to keep the
electrodes in position. Removed brains were stored in ﬁxation so-
lution (4% paraformaldehyde) for oneweek at 4 C before theywere
transferred into sucrose solution (30% in PBS). For immunohisto-
chemical staining of neurons and inﬂammation markers (reactive
microglia and astrocytes), 20 mm thin tissue slices were prepared
with a cryostat-microtome (CM 3050 S, Leica, Wetzlar, Germany)
and transferred to glass slides. Brain slices were then divided into
two groups according to their consecutive numbering (even/odd)
so that a co-staining with the cell speciﬁc markers NeuN, GFAP and
DAPI (for visualization of neurons, reactive astrocytes and cell
nuclei) could be performed on slices with even numbers and
respectively a co-staining with ED1, GFAP and DAPI (for visualiza-
tion of reactive microglia, reactive astrocytes and cell nuclei) on
slices with odd numbers. Using this technique, only three ﬂuores-
cence channels were required for imaging of the slices and high
spatial resolution could be retained by altering ED1 and NeuN
staining in steps of only 20 mm. Prior to antibody incubation, all
slices were exposed to 10% normal donkey serum (NDS) for 30 min
to block unspeciﬁc binding. Subsequently, both groups were
exposed to NeuN (mouse IgG), GFAP (polyclonal rabbit antibody)
and ED1 (mouse IgG) for 3 h. Alexa Fluor488 donkey anti mouse
(lex: 495 nm, lem: 519 nm) and Alexa Fluor647 donkey anti rabbit
(lex: 649 nm, lem: 666 nm) were used as secondary antibody and
incubated for 1 h each. Staining of cell nuclei was ensured by the
use of Dapi-Fluoromount G (lex: 358 nm, lem: 461 nm) for ﬁxing
the slices on the glass slides. Fluorescence imaging of these slices
was performed within 24 h after staining with a Nikon Eclipse Ti-S
inverted microscope (Nikon, Duesseldorf, Germany) equipped with
a CCD colour camera. Image analysis was subsequently done with
ImageJ where GFAP and ED1 ﬂuorescence intensity proﬁles in front
of the electrode were determined as measure for the immune
response to the electrode. The auto-ﬂuorescence of the polyimide
probe (observed in all ﬂuorescence channels at 461, 519 and
666 nm) enabled a precise reconstruction of the electrode sites
along the probe shaft and consequently highly accurate measure-
ments. Fluorescence intensity and thus distribution of relevant cells
was assessed in each slice along a 50 mm wide region of interest
(ROI) extending 300 mm away from the electrode surface as indi-
cated in Fig. 8b. Data obtained from all tissue slices containing a
fragment of the PEDOT-coated electrode sites were subsequently
averaged to yield an intensity-distance proﬁle for the different
animal groups. Neuron distance was measured between NeuN
stained cell bodies and PEDOT/Dex coated electrode sites along a
straight line representing the shortest distance between the two
objects.
2.8. In vitro measurements
Six PEDOT/Dex functionalized probes, fabricated equally to the
animal probes, were stored in 37 C PBS during the time course of
the animal study. During these 12weeks, three of the in vitro probes
were regularly CV-cycled in analogy to the implanted peers. All
in vitro probes received weekly impedance measurements. Data
from these probes were used to evaluate progressive impedance
and charge storage capacity (CSC) changes of the PEDOT coatings in
absence of the in vivo environment and these probes were further
used as controls for SEM imaging.
Fig. 2. a) Representative LFP data recorded after 12 weeks in vivo from 12 animals
demonstrating persistent recording capability for PEDOT/Dex and PEDOT/PSS coated
probes. Spectral analysis shows presence of low frequency LFPs over the entire study
time (b).
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based on previous work from Boehler et al. where active release of
Dex from PEDOT/Dex probes has been investigated in response to
CV cycling in vitro over multiple release events and over several
weeks [60]. Selection of an appropriate CV-range and imple-
mentation of adhesion promotion were thereby described as crit-
ical parameters for enabling Dex release and restricting EDOT
leakage. Based on this data, and with the intention to avoid unde-
sired electrochemical reactions in vivo, we choose a CV-range
of 0.3e0.45 V vs. Ag/AgCl for drug release in our animal study.
In order to account for the reduced CV range, compared to the
previously reported data (0.6e0.9 V vs. Ag/AgCl), the Dex-release
properties were re-evaluated in vitro prior to the actual animal
experiment in this work. A test electrode (4 mm diameter, in
analogy to previous work) was coated with PEDOT/Dex and
repeatedly exposed to CV-based release cycles over a total time of
45 days. Active and passive drug expulsion in PBS were analysed by
high performance liquid chromatography (HPLC) in this time frame
following the previously described protocols [60]. Drug release was
further evaluated for PEDOT/Dex coatings deposited on either
platinum or IrOx substrates to evaluate the inﬂuence of the sub-
strate material on the release characteristics. For this test, poly-
imide based probes were fabricated in analogy to the ﬁnal implants
to ensure relevant test conditions. Release characteristics of these
samples were assessed over three active release events within
150 min.
2.9. High magniﬁcation imaging of the probes
At the endpoint of the study, one of the probes carrying four
electrode sites with a PEDOT/Dex coating was explanted instead of
sliced. The probe was carefully rinsed with Milli-Q water and
transferred to PBS where CV and EIS measurements were per-
formed. The explant was further imaged by Scanning Electron
Microscopy (SEM) using a Nova NanoSEM (FEI, Hillsboro, USA) to
evaluate the status of the coating after 12 weeks in vivo. The
morphology of these PEDOT sites was subsequently compared to
SEM images of PEDOT/Dex ﬁlms exposed to CV cycling over 12
weeks in vitro as well as pristine PEDOT/Dex ﬁlms imaged directly
after electrodeposition of the coating.
2.10. Statistical analysis
Statistical signiﬁcance of data was analysed by OriginPro (Ori-
ginLab Corporation, version 2016G) and XLSTAT (Addinsoft, version
19.01) software. Anderson-Darling tests were used to conﬁrm
normal distribution of values before either Student t-tests or Wil-
coxon signed-rank-test were performed. P-values <0.01 were
considered signiﬁcant.
3. Results
3.1. In vitro drug release
The drug release proﬁle of PEDOT/Dex electrodes was investi-
gated in vitro over a time period of 45 days with active release
events on day 10, 14, 42 and 45 employing 5 CV scans (0.3e0.45 V
vs. Ag/AgCl) per release event for evaluation of release efﬁciency.
Quantiﬁcation of released Dex by HPLC analysis thereby revealed a
total amount of 805 ng of Dex being released within 45 days. 24% of
this mass were attributed to actively triggered release within
0.006% of the total experiment time, demonstrating a substantial
release in response to the CV sweeps compared to purely passive
drug elution. The largest drug expulsion was found during the ﬁrst
trigger event (114 ng) while subsequent release events featured anaverage drug expulsion of 25 ± 12 ng. Drug was thereby released
within a time of 1 min per active release event. For the passive drug
elution an average mass of 0.006 ± 0.005 ng could be measured in
the respective timeframe. Evaluation of drug release from PEDOT/
Dex ﬁlms deposited on either platinum or IrOx substrates revealed
in both cases an active contribution of 19% to the totally elutedmass
in 2% of the total time. This demonstrates that drug release char-
acteristics are not inﬂuenced by the substrate material.
3.2. Neural recordings
Electrophysiological data were collected on a weekly basis from
the implanted neural probes and used to evaluate the recording
capability of the PEDOT-coated electrode sites during the chronic
study. LFP signals from all 12 animals at week 12 post implantation
are summarized in Fig. 2a demonstrating unrestricted neural
recording functionality until the end of the study for all implanted
probes. The detailed spectral analysis of these LFP-data showed a
strong signal contribution in the low LFP band between 2 Hz and
15 Hz (Fig. 2b). This spectral compositionwas found consistent over
the 12 weeks as can be seen from the representative data at week 6
and 12 in Fig. 2b.
3.3. Electrochemical measurements in vivo
The signal employed for drug release was simultaneously used
C. Boehler et al. / Biomaterials 129 (2017) 176e187 181to calculate the CSC by integrating the total area under the CV-
curves which provides a measure for the electrode status. CSC-
values for active PEDOT/Dex animals and active PEDOT/PSSFig. 3. Electrochemical data recorded over 12 weeks in vivo for monitoring of the
PEDOT properties. CSC (a), Impedance magnitude (b) and phase angle (c) display
averaged data for the different animal groups with standard deviation as error bars
(n ¼ 16). The horizontal line indicates statistical difference for active PEDOT/PSS
(p < 0.01).animals are summarized in Fig. 3a where each data point repre-
sents the average over 4 probes from 4 animals (n ¼ 16). For both
animal groups, an increase in the CSC can be seen with progressive
time while the absolute CSC for the PEDOT/Dex probes was found
overall higher compared to the PEDOT/PSS controls by an average
factor of 2.1. The observed difference between the two groups was
however not statistically signiﬁcant (p > 0.01) over the 12 weeks.
Between week 2 and week 10 post implantation a CSC increase of
91% (from 3.6 to 6.8 mC cm2) and 120% (from 1.4 to 3.0 mC cm2)
for the PEDOT/Dex probes and the PEDOT/PSS probes could be
measured respectively. The increase for PEDOT/PSS controls was
thereby statistically signiﬁcant (p < 0.01) whereas the increase for
PEDOT/Dex probes was not statistically signiﬁcant (p > 0.01).
Electrochemical impedance spectroscopy (EIS) data, recorded
over 12 weeks and averaged within the three animal groups, was
further used to verify the status of the polymer electrodes while
being implanted. Results from these measurements are displayed
in Fig. 3b for the impedance magnitude and Fig. 3c for the corre-
sponding phase angle. Based on the main signal contribution in the
low LFP spectrum (between 2 and 15 Hz), a frequency of 8 Hz has
been chosen for comparing the different polymer coatings. The
active PEDOT/Dex probes showed initially the lowest impedance
until week four post implantation when an increase could be seen
from 260 kU at week two to 533 kU at week 12. The impedance for
the passive PEDOT/Dex probes was found consistently higher from
the beginning with 559 kU at week two and 544 kU at week 12.
While the PEDOT/PSS probes featured an initial impedance of
302 kU at week two, these probes were measured with the lowest
impedance at the end of the study (379 kU at week 12). Besides
these impedance alterations within the different animal groups it is
however worth mentioning that overall a maximum impedance
change of a factor two could be seen during the entire study which
is here considered as stable impedance behaviour. Variability in
impedance data within the three test groups (data averaged over 4
animals) could also be seen within individual animals. Further-
more, no statistically signiﬁcant differences (p > 0.01) in the
impedance data were observed between the different groups. The
same impedance behaviour could be observed at a frequency of
1 kHz for the different coatings (data not shown), demonstrating
that impedancewas stable regardless of frequency. The phase angle
showed a slight decrease over the 12 weeks from 45 to 54
(þ20%) for the active PEDOT/Dex probes, 39 to 45 (þ15%) for
the active PEDOT/PSS probes and 48 to 52 (þ8%) for the
passive PEDOT/Dex implants (Fig. 3c). The observed decrease was
thereby not statistically signiﬁcant.
The full impedance spectrum recorded from 1 Hz to 10 kHz is
displayed in Fig. 4 for all material groups at week 12 post implan-
tation (n ¼ 16). All coating types feature similar impedance char-
acteristics over the full frequency spectrum as seen in the
impedance magnitude (Fig. 4a) and for the phase angle (Fig. 4b).
Impedance values close to a frequency of 50 Hz were inﬂuenced by
noise from the 50 Hz power supply and therefore show the highest
variations in the measurement. Average phase angles over the
complete frequency spectrum were 54 (±14), 53 (±14)
and 53 (±12) for active PEDOT/PSS, active PEDOT/Dex and
passive PEDOT/Dex groups respectively (n ¼ 160).
3.4. Electrochemical measurements in vitro
In parallel to the in vivo experiments, six PEDOT/Dex coated
probes were exposed to 37 C PBS over 12 weeks for monitoring the
electrode properties in vitro and providing reference data to the
implanted probes. CV and impedance measurements were per-
formed in analogy to the implanted peers on weekly basis. The CSC
data from three actuated probes is shown in Fig. 5a where a
Fig. 4. EIS spectrum recorded at week 12 post implantation shows similar character-
istics for all animal groups in the impedance magnitude (a) and for the phase angle (b).
Error bars denote standard deviation (n ¼ 16).
Fig. 5. Electrochemical data measured in vitro from three PEDOT/Dex probes. Averaged
data for CSC (a), impedance magnitude (b) and phase angle (c) originate from n ¼ 12
electrode sites, error bars denote standard deviation. The horizontal line indicates
statistical difference (p < 0.01).
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0.73 mC cm2 can be seen with progressing storage time. The CSC-
increment of 26% betweenweek two andweek 10was substantially
lower compared to the in vivo probes (91% increase). Furthermore,
the values measured in vitrowere found overall lower compared to
the CSC measured in vivo (e.g. 0.73 ± 0.09 mCcm2 vs.
6.7 ± 4.2 mCcm2 at week 10 post implantation).
Fig. 5b displays the impedancemagnitude at 8 Hz, averaged over
all in vitro-probes. During the storage time of 12 weeks, a statisti-
cally signiﬁcant increase (p < 0.01) in the impedance can be seen,
approaching a value of 270 kU towards the end of themeasurement
time. This value represents half of what has been measured for the
active PEDOT/Dex probes during the in vivo measurements
(533 kU). The phase angle in the in vitro EIS measurements (dis-
played in Fig. 5c) shows a progressive decrease during the experi-
ment time from 71 at week two to 79 at week 12. The
difference of 11% is thereby similar to the changes observed from
the in vivo data (20%). An offset of 20 between the phase angles
determined in vivo and in vitro could be measured, attributed to the
different complexity of the electrolytes. Optical microscopy
revealed that all PEDOT coatings were fully intact and adherent to
the in vitro probes after 12 weeks in PBS storage.3.5. Examination of the explanted probe
At the endpoint of the study, one PEDOT/Dex probe was
Fig. 6. Comparison of CSC (a) and impedance magnitude (b) for a PEDOT/Dex coated
probe before implantation and after 12 weeks in vivo. Error bars denote standard
deviation (n ¼ 4). High resolution SEM shows fully intact PEDOT/Dex coatings after 12
weeks of implantation (c) during which 30 CVs have been applied for drug release.
Dark areas in the higher magniﬁcation image result from tissue residues after
explantation. The morphology of explanted PEDOT/Dex coatings (f) is comparable to
PEDOT/Dex ﬁlms exposed to in vitro stimulation over 12 weeks (e) and shows larger
grains in comparison to a pristine polymer ﬁlm directly imaged after polymerization
(d).
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SEM imaging to verify the status of the coating. In Fig. 6a the CSC for
the explanted probe is compared to the corresponding values
before the probe was implanted and to an uncoated IrOx surface.
After deposition of the PEDOT/Dex, the CSC was measured with
2.78 mCcm2 which represents an increase of 28% compared to the
uncoated IrOx (2.18 mCcm2). Following explantation and rinsing
of the probe with PBS, a CSC of 7.15 mCcm2 could be measured
which is 2.57 times higher compared to the status before implan-
tation. From the impedance data in Fig. 6b it can further be seen
that the impedance of the electrode sites was lower when
measured after explantation (153 kU at 8 Hz) compared to the
status before implantation (239 kU at 8 Hz). The impedance of the
uncoated IrOx was overall highest with 304 kU at a frequency of
8 Hz. Comparing the low impedance after 12 weeks in vivowith the
initial values of IrOx demonstrates that the polymer coating was
still intact at the endpoint of the study. This observation could be
conﬁrmed by SEM imaging of the probe where a homogenous
coverage of the electrode sites with PEDOT/Dex could be seen
(Fig. 6c). Higher magniﬁcation of the electrode sites revealed a
highly roughened surface of the polymer coating for the explant
(Fig. 6f) which is comparable to the morphology of a PEDOT/Dex
sample stimulated over 12 weeks in vitro (Fig. 6e). Both probes
thereby revealed a larger grain size in comparison to a pristine
PEDOT/Dex sample (Fig. 6d) indicating a morphological change for
the exposed coatings during the 12 weeks which explains the
observed changes in CSC and EIS.
3.6. Immunohistochemical analysis
In order to evaluate the intensity of the foreign body reaction
towards the implanted probes after 12 weeks in vivo, the retrieved
tissue was horizontally sliced, with the probe remaining in the
tissue, and immunohistochemically stained. Staining was thereby
done for GFAP, NeuN and ED1 which provides information about
the chronic formation of scar tissue, neuron survival and microglia
activity in the probe vicinity respectively. By keeping the probe in
the tissue during slicing, and making use of the auto-ﬂuorescence
of the polyimide substrate, it was possible to precisely identify
the exact location of the PEDOT-coated electrode sites from the
histology pictures (Fig. 7). Quantitative image analysis could
therefore be performed with direct correlation to the coated sites
along the probe shaft. Fig. 8a displays the measured distance be-
tween the electrode sites and the nearest neurons identiﬁed from
NeuN stained images. With a distance of only 10 mm, the closest
neurons were found in front of the active PEDOT/Dex probes as well
as the passive IrOx implants. For the remaining PEDOT coatings, a
minimal distance of 16e30 mm could be measured. The average
neuron to electrode distance for all investigated materials was
between 48 and 83 mm with the lowest distance observed for the
active PEDOT/Dex probes. Differences in mean neuron distance
between the different sample groups were however not statistically
signiﬁcant (p > 0.01).
GFAP ﬂuorescence intensity was used to evaluate the thickness
of the astrocytic scar tissue which formed around the electrode
within the 12 weeks study. Fluorescence intensity proﬁles along a
300 mm long ROI extending from the probe surface (see inset in
Fig. 8b) were averaged over all slices per animal group. An overall
decrease in the intensity within a distance of 75 mm from the
electrode site could be seen for all samples (Fig. 8b). GFAP ﬂuo-
rescence, and thus astrocyte scar formation, was found lowest at
the electrode surface for the IrOx probes while all PEDOT coated
probes showed similar astrocyte counts in close distance to the
probe surface, regardless of the counter ion. The observed differ-
ence between the IrOx control and passive PSS probes was not
Fig. 7. Auto-ﬂuorescent polyimide probes permit simple probe identiﬁcation in his-
tology and enable precise correlation of tissue reactions with functionalized areas on
the probe.
Fig. 8. Neuron distance (a) and GFAP ﬂuorescence intensity (b) for different coating
materials on the polyimide probes. The inset in (b) shows the path along which the
GFAP ﬂuorescence intensity was measured and averaged using a 50 mmwide ROI. Data
represents average over n ¼ 30, error bars in a) denote standard deviation.
Fig. 9. ED1-staining for microglia activity shows lower intensity for PEDOT/Dex probes
compared to PEDOT/PSS controls.
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were signiﬁcant (p < 0.01) within 30 mm (active PSS), 35 mm
(passive PSS) and 70 mm (active Dex) between IrOx and the
respective polymer coated probes. At distances exceeding 75 mm
from the electrode surface, no difference in GFAP staining between
the tested materials could be seen resulting in a baseline level of
astrocyte density at 75e300 mm distance. This baseline level couldfurther be conﬁrmed by GFAP measurements from reference tissue
slices at different implantation depths and locations, corresponding
to inﬂammation-free tissue. Differences in GFAP intensity among
the polymer coated probes were not statistically signiﬁcant
(p > 0.01).
ED1-staining, representing activated macrophages/microglia,
showed a lower intensity in close vicinity to the PEDOT/Dex probes
as compared to PEDOT/PSS probes as can be seen from the ﬂuo-
rescence intensity proﬁles in Fig. 9. This difference was however
not found to be statistically signiﬁcant (p > 0.01). Active or passive
probes within these two material classes thereby only showed
minor differences in ED1 intensity. The overall lowest microglia
intensity could be found directly in front of the IrOx implants, the
difference to the polymer coated probes was however not statisti-
cally signiﬁcant. At distances exceeding 20 mm from the electrode
surface, no difference between the probes types could be observed
in ED1 ﬂuorescence.4. Discussion
Neural microprobes provide excellent opportunities for
biomedical research and clinical applications by providing highly
selective recording or stimulation of neural tissue. Following im-
plantation, these probes however inevitably trigger a foreign body
response leading to chronic scar tissue formation which ultimately
affects usability in long-term applications.
This study combines two of the most promising technologies for
making long-term stable connection to neuronal tissue possible
over chronic periods of time: ﬂexible probes and anti-inﬂammatory
treatment in the form of local drug delivery. Dex release from
ﬂexible thin-ﬁlm probes, implanted in the rat hippocampus, was
studied over a period of 12 weeks which is to our knowledge the
ﬁrst time that active driven drug release has been investigated
in vivo over such a long period of time.
Dex has previously been tested as anti-inﬂammatory treatment
either administered locally by passive eluting systems [33,35e42,45]
or in the form of systemic treatment [34,67]. In the latter case,
practical applicability has however been limited considering the
high systemic dose needed in order to reach efﬁcient levels locally at
the surface of an implant. Dex is a corticosteroid drug and has well
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PEDOT release system circumvents the systemic side effects by
enabling highly local administration of the drug directly at the
electrode site. Furthermore, and in contrast to coatings based on
biodegradation or diffusion for delivery, it offers superior temporal
control over release. Dosage of a drug can thereby be scheduled to
speciﬁc time points over a relatively long time frame, or even be
provided in response to a surveillance parameter, e.g. related to
inﬂammation status.
We here test the hypothesis that anti-inﬂammatory treatment,
extending beyond the initial healing phase of six weeks, could have
an impact on probe-tissue integration also on the longer perspec-
tive. Our study covers 12 weeks which extends well into what is
generally considered to be representative for chronic conditions.
Data collected over this time frame indicate that electrodes
exposed to an active Dex delivery protocol on a weekly basis did
have neurons closer to the electrode sites than any of the control
materials in the study. Such a neuron-protective effect of Dex has
previously been assumed from in vitro studies [53] and could be
supported from our chronic measurements in vivo. Given the
relatively small number of animals and probes included in the
study, and the small differences seen, it is however not possible to
draw any statistically signiﬁcant conclusion (p > 0.01) on the pos-
itive impact of Dex on overall probe performance. In fact, the use of
ﬂexible polyimide probes already reduced the extent of inﬂam-
mation to a level where the criteria for stable recordings are already
fulﬁlled regardless of the electrode coating material. Nevertheless,
several important conclusions can be drawn pointing the way for
future work with anti-inﬂammatory electrodes.
Over a period of 12weeks we performed in total 320 stimulation
sessions with either PEDOT/Dex or PEDOT/PSS coated electrode
sites in three electrode conﬁguration in vivo. Working, counter- and
reference-electrode were thereby directly integrated in close
proximity on the ﬂexible probe, demonstrating that controlled
delivery from a three-electrode cell in vivo is feasible from a single
thin-ﬁlm based device. During CV stimulations, we could not
observe any reaction or sensation in the fully awake animals. This
implies that active drug release was performed sub threshold for
evoking a neural response. Additionally, we could neither optically
nor electrochemically determine any changes to the electrode
surfaces nor observe increased inﬂammation in histology in
response to the swept voltage. Similar observations have been
made in a recent study by Alba et al. where CV sweeps from 0.9 V
to 0.6 V (vs. Pt) were employed for monitoring the CSC for multi-
walled carbon nanotube (MWCNT)/Dex modiﬁed electrodes in the
visual cortex of anesthetized rats [66]. Despite applying more than
200 CV scans during 11 days in their study, they did not observe any
changes to the electrode nor any tissue alterations or any inﬂuence
on the recorded signals in correlation to the CV sweeping. It can
thus be concluded that CV cycling is a suitable and, within the
herein described boundaries, also safe method to be used for drug
release in vivo in fully awake animals. This is important considering
that CV signals have been reported to be most efﬁcient for driving
controlled release of drugs from conducting polymer ﬁlms
[53,59,68].
Furthermore, the previously reported release of by-products in
the form of monomers or oligomers [60] could be efﬁciently
controlled by limiting the sweep range in our study, supported by
the observation that no additional inﬂammation was triggered by
the release cycles. The limitation of the sweep range thereby did
not affect the drug release itself as could be demonstrated in a long-
term in vitro study over 45 days.
Our Dex-functionalized implants featured an overall drug load
of 19 ng per probe, based on the polymerization charge and the
doping ratio of PEDOT/Dex. Adopting a tissue volume of400 400 400 mm3 (in relation to the width of the implant) to be
treated over 12 weeks, this would allow a Dex concentration of
6.8 mM if the entire drug load is spent over this time. Previous
studies have reported on Dex concentrations of 0.2e0.7 mM [53] or
4.5 pg [69] to be efﬁcient for therapeutic cell interaction. This
means even if we assume that only a fraction (e.g.1/10th) of the Dex
is released from our PEDOT/Dex coated microprobes over time, the
concentration in the tissue would still be high enough demon-
strating that electropolymerized PEDOT/Dex coatings with
300 mC cm2 provide sufﬁcient drug storage and release capacity
for at least 12 weeks of operation. The maximal drug mass that
could theoretically be released from our probes (19 ng) is thereby
more than 4 orders of magnitude lower than the neurotoxic levels
of Dex reported for hippocampal cells [70].
All PEDOT ﬁlms were stable over the full 12 weeks which is
evident from the monitored impedance data. Stability of the coat-
ings could furthermore be veriﬁed bymicroscopy and SEM imaging
of the explanted sample. Based on previously reported results by
Boehler et al. [62], such stability is expected for PEDOT/PSS on IrOx
but is especially encouraging for PEDOT/Dex which is expected to
be more fragile due to the high mobility of the counter ion and the
associated mechanical stress in the ﬁlm during release. The
observed stability proves that IrOx is a highly efﬁcient strategy for
stabilizing PEDOT ﬁlms also under in vivo conditions and thereby
conﬁrms our ﬁndings from previous in vitro work [62].
By using a ﬂexible substrate material for the probes in our study
we were able to keep the entire probe in the tissue during the
preparation of histological slices. This technique allowed a precise
reconstruction of the actual electrode sites in histology and
consequently enabled the direct analysis of tissue in front of the
recording/stimulation sites. Examining the number and position of
embedded metal tracks, visible in the probe cross-section in his-
tological images, further provided a “bar code” feature which
served as simplemethod for identiﬁcation of speciﬁc electrode sites
along the probe shaft.
An unexpected ﬁnding is that bare IrOx electrodes out-
performed all the PEDOT materials which raises the question
whether there are negative effects of PEDOT as such? Considering
the large number of studies where PEDOT has been investigated
without reporting on negative effects in the literature, this would
indeed be a surprising ﬁnding. A more likely explanation is the
different preconditions in our study where the polyimide probes
are exposed to the monomer EDOT during PEDOT deposition,
whereas IrOx probes are used as produced in the cleanroom and
were never immersed in the monomer solution. We could in fact
conﬁrm by HPLC analysis that slight residues from the electrode-
position process are present and released from the polyimide sur-
face, bringing them eventually into tissue contact upon probe
implantation. Although most of these residues are expected to be
cleaned away during immersion of the probes in PBS overnight
prior to implantation, further leaching of remaining contamina-
tions over several weeks could be the reason for the slightly
elevated inﬂammation seen around all PEDOT-coated probes in
comparison to the IrOx controls. In our study IrOx therefore only
has limited suitability as control and tissue reactions should be
analysed separately for all PEDOT coated probes. Contaminations
from electrolyte residuals could in the future be addressed by
improved post-deposition cleaning protocols. The fact that mono-
mer contaminations could be eluted shows that this would indeed
be possible by simple immersion in aqueous solutions.
We here show a method for how to use PEDOT/drug systems for
local release in vivo employing ﬂexible probe technology and three-
electrode cell electrochemistry on a single thin-ﬁlm device with
promising qualities. The ﬂexible polyimide devices thereby overall
performed exceptionally well regardless of the coating material on
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ﬂexible probes has long been limited due to difﬁculties in precise
implantation of such probes. A considerable effort has been
invested into developing insertion methods allowing ﬂexible
probes to be implanted into brain tissue without buckling or
introducing severe tissue damages. We here use a stiff device
(optical ﬁbre) as insertion shuttle and conﬁrm that precise im-
plantation of a 10 mm thin ﬂexible probe into the rat hippocampus
is possible without signiﬁcantly harming the surrounding tissue.
Although not evaluated or performed in this study, implantation
with an optical ﬁbre as guiding tool could in future also be com-
bined with techniques such as optical coherence tomography [71].
By suchmeans, the guidance ﬁbre could provide optical monitoring
of the insertion track and thus help to prevent vascular damages or
provide improved targeting accuracy within the brain.
Flexible probes generally provide attractive alternatives to stiff
implants with respect to tissue reactivity. Nevertheless, stiff im-
plants still provide an important probe technology that cannot
readily be replaced by ﬂexible materials in all applications.
Controlled release of anti-inﬂammatory drugs should therefore
also be tested with stiff devices where inﬂammation is expected to
be more prominent and thus of higher concerns for long-term
applications. We here show that such implementation is techni-
cally feasible, however, the effect should still be investigated in
combination with stiff probes. Further development of anti-
inﬂammatory electrodes targeting the incorporation of different
drugs or investigating the appropriate release timing for optimal
treatment efﬁciency with active drug release technology should be
performed. If release is thereby coupled to a surveillance parameter
monitoring the extent of inﬂammation directly at the electrode site,
an individual and thus optimal inﬂammation treatment could be
enabled.
5. Conclusion
In conclusion we were able to demonstrate that Dex function-
alized PEDOT can be integrated as anti-inﬂammatory electrode
coating on ﬂexible neural microprobes providing unrestricted
neural recording properties and low, long-term stable impedance
characteristics. Actively controlled release of Dex was possible over
12 weeks using a CV trigger signal in awake animals and data in-
dicates that electrodes exposed to active drug release did have
neurons closer to the electrode sites compared to controls,
although the effect was not statistically signiﬁcant. Combining
ﬂexible probe technology with anti-inﬂammatory coatings there-
fore proves to be a promising approach for enabling long-term
stable chronic neural interfaces and should be further developed
towards future anti-inﬂammatory electrode generations.
Acknowledgement
This work was supported by the Cluster of Excellence
BrainLinks-BrainTools, funded by the German Research Foundation
(DFG, grant number EXC 1086).
References
[1] C.-J. Li, Y. Lu, M. Zhou, L.-J. Guo, Electrophysiological properties of hippo-
campalecortical neural networks, role in the processes of learning and
memory in rats, J. Neural Transm. 121 (2014) 583e592.
[2] M. Weinrich, S.P. Wise, K.H. Mauritz, A neurophysiological study of the pre-
motor cortex in the rhesus monkey, Brain A J. Neurol 107 (1984) 385.
[3] G. Buzsaki, Z. Horvath, R. Urioste, J. Hetke, K. Wise, High-frequency network
oscillation in the hippocampus, Science 256 (1992) 1025e1027.
[4] G. Buzsaki, Large-scale recording of neuronal ensembles, Nat. Neurosci. 7
(2004) 446e451.
[5] D.M. Thompson, A.N. Koppes, J.G. Hardy, C.E. Schmidt, Electrical stimuli in thecentral nervous system microenvironment, Annu. Rev. Biomed. Eng. 16 (2014)
397e430.
[6] P.E. Holtzheimer, H.S. Mayberg, Deep brain stimulation for psychiatric disor-
ders, Annu. Rev. Neurosci. 34 (2011) 289e307.
[7] T. Stieglitz, B. Rubehn, C. Henle, S. Kisban, S. Herwik, P. Ruther, et al.,
Brainecomputer interfaces: an overview of the hardware to record neural
signals from the cortex, in: E.M.H.I.H.J.W.A.B.B.G.J.B. Joost Verhaagen, F.S. Dick
(Eds.), Progress in Brain Research, Elsevier, 2009, pp. 297e315.
[8] M.L. Homer, A.V. Nurmikko, J.P. Donoghue, L.R. Hochberg, Implants and
decoding for intracortical brain computer interfaces, Annu. Rev. Biomed. Eng.
15 (2013) 383e405.
[9] R.A. Normann, E.M. Maynard, P.J. Rousche, D.J. Warren, A neural interface for a
cortical vision prosthesis, Vis. Res. 39 (1999) 2577e2587.
[10] W.M. Grill, Signal considerations for chronically implanted electrodes for
brain interfacing, in: W.M. Reichert (Ed.), Indwelling Neural Implants: Stra-
tegies for Contending with the in Vivo Environment, Taylor & Francis Group,
LLC, Boca Raton FL, 2008.
[11] V.S. Polikov, P.A. Tresco, W.M. Reichert, Response of brain tissue to chronically
implanted neural electrodes, J. Neurosci. Methods 148 (2005) 1e18.
[12] S. Franz, S. Rammelt, D. Scharnweber, J.C. Simon, Immune responses to im-
plants e a review of the implications for the design of immunomodulatory
biomaterials, Biomaterials 32 (2011) 6692e6709.
[13] T.D. Kozai, A.L. Vazquez, C.L. Weaver, S.G. Kim, X.T. Cui, In vivo two-photon
microscopy reveals immediate microglial reaction to implantation of micro-
electrode through extension of processes, J. neural Eng. 9 (2012) 066001.
[14] R. Biran, D.C. Martin, P.A. Tresco, Neuronal cell loss accompanies the brain
tissue response to chronically implanted silicon microelectrode arrays, Exp.
Neurol. 195 (2005) 115e126.
[15] D.H. Szarowski, M.D. Andersen, S. Retterer, A.J. Spence, M. Isaacson,
H.G. Craighead, et al., Brain responses to micro-machined silicon devices,
Brain Res. 983 (2003) 23e35.
[16] B.D. Winslow, P.A. Tresco, Quantitative analysis of the tissue response to
chronically implanted microwire electrodes in rat cortex, Biomaterials 31
(2010) 1558e1567.
[17] T.D.Y. Kozai, N.B. Langhals, P.R. Patel, X. Deng, H. Zhang, K.L. Smith, et al.,
Ultrasmall implantable composite microelectrodes with bioactive surfaces for
chronic neural interfaces, Nat. Mater. 11 (2012) 1065e1073.
[18] A.B. Schwartz, Cortical neural prosthetics, Annu. Rev. Neurosci. 27 (2004)
487e507.
[19] G.C. McConnell, H.D. Rees, A.I. Levey, C.A. Gutekunst, R.E. Gross,
R.V. Bellamkonda, Implanted neural electrodes cause chronic, local inﬂam-
mation that is correlated with local neurodegeneration, J. neural Eng. 6 (2009)
056003.
[20] R.W. Grifﬁth, D.R. Humphrey, Long-term gliosis around chronically implanted
platinum electrodes in the Rhesus macaque motor cortex, Neurosci. Lett. 406
(2006) 81e86.
[21] W.M. Grill, S.E. Norman, R.V. Bellamkonda, Implanted neural interfaces: bio-
challenges and engineered solutions, Annu. Rev. Biomed. Eng. 11 (2009)
1e24.
[22] M. Welkenhuysen, A. Andrei, L. Ameye, W. Eberle, B. Nuttin, Effect of insertion
speed on tissue response and insertion mechanics of a chronically implanted
silicon-based neural probe, IEEE Trans. Biomed. Eng. 58 (2011) 3250e3259.
[23] J.P. Seymour, D.R. Kipke, Neural probe design for reduced tissue encapsulation
in CNS, Biomaterials 28 (2007) 3594e3607.
[24] T. Stieglitz, H. Beutel, M. Schuettler, J.U. Meyer, Micromachined, polyimide-
based devices for ﬂexible neural interfaces, Biomed. Microdevices 2 (2000)
283e294.
[25] P.J. Rousche, D.S. Pellinen, D.P. Pivin, J.C. Williams, R.J. Vetter, D.R. Kipke,
Flexible polyimide-based intracortical electrode arrays with bioactive capa-
bility, IEEE Trans. Biomed. Eng. 48 (2001) 361e371.
[26] P. Moshayedi, G. Ng, J.C.F. Kwok, G.S.H. Yeo, C.E. Bryant, J.W. Fawcett, et al.,
The relationship between glial cell mechanosensitivity and foreign body re-
actions in the central nervous system, Biomaterials 35 (2014) 3919e3925.
[27] K.C. Cheung, P. Renaud, H. Tanila, K. Djupsund, Flexible polyimide micro-
electrode array for in vivo recordings and current source density analysis,
Biosens. Bioelectron. 22 (2007) 1783e1790.
[28] A. Mercanzini, K. Cheung, D.L. Buhl, M. Boers, A. Maillard, P. Colin, et al.,
Demonstration of cortical recording using novel ﬂexible polymer neural
probes, Sensors Actuators A Phys. 143 (2008) 90e96.
[29] T.D. Kozai, A.S. Jaquins-Gerstl, A.L. Vazquez, A.C. Michael, X.T. Cui, Brain tissue
responses to neural implants impact signal sensitivity and intervention stra-
tegies, ACS Chem. Neurosci. 6 (2015) 48e67.
[30] C. Hassler, J. Guy, M. Nietzschmann, D.T.T. Plachta, J.F. Staiger, T. Stieglitz,
Intracortical polyimide electrodes with a bioresorbable coating, Biomed.
Microdevices 18 (2016) 81.
[31] A. Richter, Y. Xie, A. Schumacher, S. Loefﬂer, R. Kirch, J. Al-Hasani, et al.,
A simple implantation method for ﬂexible, multisite microelectrodes into rat
brains, Front. Neuroeng. (2013) 6.
[32] E. Azemi, C.F. Lagenaur, X.T. Cui, The surface immobilization of the neural
adhesion molecule L1 on neural probes and its effect on neuronal density and
gliosis at the probe/tissue interface, Biomaterials 32 (2011) 681e692.
[33] T. Hickey, D. Kreutzer, D.J. Burgess, F. Moussy, In vivo evaluation of a dexa-
methasone/PLGA microsphere system designed to suppress the inﬂammatory
tissue response to implantable medical devices, J. Biomed. Mater. Res. 61
(2002) 180e187.
C. Boehler et al. / Biomaterials 129 (2017) 176e187 187[34] W.K. Ward, J.C. Hansen, R.G. Massoud, J.M. Engle, M.M. Takeno, K.D. Hauch,
Controlled release of dexamethasone from subcutaneously-implanted bio-
sensors in pigs: localized anti-inﬂammatory beneﬁt without systemic effects,
J. Biomed. Mater. Res. Part A 94A (2010) 280e287.
[35] S.D. Patil, F. Papadmitrakopoulos, D.J. Burgess, Concurrent delivery of dexa-
methasone and VEGF for localized inﬂammation control and angiogenesis,
J. Control. Release 117 (2007) 68e79.
[36] M.J. Webber, J.B. Matson, V.K. Tamboli, S.I. Stupp, Controlled release of
dexamethasone from peptide nanoﬁber gels to modulate inﬂammatory
response, Biomaterials 33 (2012) 6823e6832.
[37] W. Shain, L. Spataro, J. Dilgen, K. Haverstick, S. Retterer, M. Isaacson, et al.,
Controlling cellular reactive responses around neural prosthetic devices using
peripheral and local intervention strategies, Neural Syst. Rehabilitation Eng.
IEEE Trans. 11 (2003) 186e188.
[38] Y. Zhong, G.C. McConnell, J.D. Ross, S.P. DeWeerth, R.V. Bellamkonda, A novel
dexamethasone-releasing, anti-inﬂammatory coating for neural implants,
Neural Engineering, in: Conference Proceedings 2nd International IEEE EMBS
Conference on 2005, 2005, pp. 522e525.
[39] Y. Zhong, R.V. Bellamkonda, Dexamethasone-coated neural probes elicit
attenuated inﬂammatory response and neuronal loss compared to uncoated
neural probes, Brain Res. 1148 (2007) 15e27.
[40] B.S. Zolnik, D.J. Burgess, Evaluation of in vivoein vitro release of dexameth-
asone from PLGA microspheres, J. Control. Release 127 (2008) 137e145.
[41] T.D. Kozai, A.S. Jaquins-Gerstl, A.L. Vazquez, A.C. Michael, X.T. Cui, Dexa-
methasone retrodialysis attenuates microglial response to implanted probes
in vivo, Biomaterials 87 (2016) 157e169.
[42] D.-H. Kim, D.C. Martin, Sustained release of dexamethasone from hydrophilic
matrices using PLGA nanoparticles for neural drug delivery, Biomaterials 27
(2006) 3031e3037.
[43] K.A. Potter, M. Jorﬁ, K.T. Householder, E.J. Foster, C. Weder, J.R. Capadona,
Curcumin-releasing mechanically adaptive intracortical implants improve the
proximal neuronal density and bloodebrain barrier stability, Acta Biomater.
10 (2014) 2209e2222.
[44] U. Bhardwaj, R. Sura, F. Papadimitrakopoulos, D.J. Burgess, Controlling acute
inﬂammation with fast releasing dexamethasone-PLGA microsphere/PVA
hydrogel composites for implantable devices, J. diabetes Sci. Technol. 1 (2007)
8e17.
[45] L.W. Norton, H.E. Koschwanez, N.A. Wisniewski, B. Klitzman, W.M. Reichert,
Vascular endothelial growth factor and dexamethasone release from non-
fouling sensor coatings affect the foreign body response, J. Biomed. Mater. Res.
Part A 81A (2007) 858e869.
[46] X. Cui, V.A. Lee, Y. Raphael, J.A. Wiler, J.F. Hetke, D.J. Anderson, et al., Surface
modiﬁcation of neural recording electrodes with conducting polymer/
biomolecule blends, J. Biomed. Mater. Res. 56 (2001) 261e272.
[47] X.T. Cui, D.D. Zhou, Poly (3,4-ethylenedioxythiophene) for chronic neural
stimulation, IEEE Trans. Neural Syst. Rehabilitation Eng. 15 (2007) 502e508.
[48] A.L. Kip, B.L. Nicholas, D.J. Mike, M.R.-B. Sarah, L.H. Jeffrey, R.K. Daryl, Poly(3,4-
ethylenedioxythiophene) (PEDOT) polymer coatings facilitate smaller neural
recording electrodes, J. Neural Eng. 8 (2011) 014001.
[49] M. Asplund, T. Nyberg, O. Inganas, Electroactive polymers for neural in-
terfaces, Polym. Chem. 1 (2010) 1374e1391.
[50] D. Svirskis, J. Travas-Sejdic, A. Rodgers, S. Garg, Electrochemically controlled
drug delivery based on intrinsically conducting polymers, J. Control. Release
Off. J. Control. Release Soc. 146 (2010) 6e15.
[51] V. Pillay, T.-S. Tsai, Y.E. Choonara, L.C. du Toit, P. Kumar, G. Modi, et al.,
A review of integrating electroactive polymers as responsive systems for
specialized drug delivery applications, J. Biomed. Mater. Res. Part A 102 (6)
(2014) 2039e2054.
[52] B. Alshammary, F.C. Walsh, P. Herrasti, C. Ponce de Leon, Electrodepositedconductive polymers for controlled drug release: polypyrrole, J. Solid State
Electrochem 20 (2016) 839e859.
[53] R. Wadhwa, C.F. Lagenaur, X.T. Cui, Electrochemically controlled release of
dexamethasone from conducting polymer polypyrrole coated electrode,
J. Control. Release Off. J. Control. Release Soc. 110 (2006) 531e541.
[54] M.R. Abidian, D.H. Kim, D.C. Martin, Conducting-polymer nanotubes for
controlled drug release, Adv. Mater. 18 (2006) 405e409.
[55] B. Massoumi, A. Entezami, Electrochemically controlled binding and release of
dexamethasone from conducting polymer bilayer ﬁlms, J. Bioact. Compatible
Polym. 17 (2002) 51e62.
[56] G. Stevenson, S.E. Moulton, P.C. Innis, G.G. Wallace, Polyterthiophene as an
electrostimulated controlled drug release material of therapeutic levels of
dexamethasone, Synth. Met. 160 (2010) 1107e1114.
[57] S. Sirinrath, P. Rajesh, J.W. Thomas, Electrically controlled drug release from
nanostructured polypyrrole coated on titanium, Nanotechnology 22 (2011)
085101.
[58] L. Leprince, A. Dogimont, D. Magnin, S. Demoustier-Champagne, Dexameth-
asone electrically controlled release from polypyrrole-coated nanostructured
electrodes, J. Mater Sci. Mater Med. 21 (2010) 925e930.
[59] Y. Xiao, X. Ye, L. He, J. Che, New carbon nanotubeeconducting polymer
composite electrodes for drug delivery applications, Polym. Int. 61 (2012)
190e196.
[60] C. Boehler, M. Asplund, A detailed insight into drug delivery from PEDOT
based on analytical methods: effects and side effects, J. Biomed. Mater. Res.
Part A 103 (2015) 1200e1207.
[61] J.S. Ordonez, C. Boehler, M. Schuettler, T. Stieglitz, Improved polyimide thin-
ﬁlm electrodes for neural implants, in: Annual International Conference of
the IEEE Engineering in Medicine and Biology Society 2012, 2012, pp.
5134e5137.
[62] C. Boehler, F. Oberueber, S. Schlabach, T. Stieglitz, M. Asplund, Long-term
stable adhesion for conducting polymers in biomedical applications: IrOx and
nanostructured platinum solve the chronic challenge, ACS Appl. Mater. In-
terfaces 9 (1) (2017) 189e197.
[63] S.X.Y. L€ofﬂer, P. Detemple, A. Moser, U.G. Hofmann, An implantation tech-
nique for polyimide based ﬂexible array probes facilitating neuronavigation
and chronic implantation, Biomed. Tech. 57 (2012) 860e863.
[64] M.W. Shinwari, D. Zhitomirsky, I.A. Deen, P.R. Selvaganapathy, M.J. Deen,
D. Landheer, Microfabricated reference electrodes and their biosensing ap-
plications, Sensors 10 (2010) 1679e1715.
[65] H. Yang, S.K. Kang, C.A. Choi, H. Kim, D.-H. Shin, Y.S. Kim, et al., An iridium
oxide reference electrode for use in microfabricated biosensors and biochips,
Lab a Chip 4 (2004) 42e46.
[66] N. Alba, Z. Du, K. Catt, T. Kozai, X. Cui, In vivo electrochemical analysis of a
PEDOT/MWCNT neural electrode coating, Biosensors 5 (2015) 618.
[67] L. Spataro, J. Dilgen, S. Retterer, A.J. Spence, M. Isaacson, J.N. Turner, et al.,
Dexamethasone treatment reduces astroglia responses to inserted neuro-
prosthetic devices in rat neocortex, Exp. Neurol. 194 (2005) 289e300.
[68] M. Asplund, C. Boehler, T. Stieglitz, Anti-inﬂammatory polymer electrodes for
glial scar treatment, Front. Neuroeng. 7 (2014) 1e11.
[69] A. Mercanzini, S.T. Reddy, D. Velluto, P. Colin, A. Maillard, J.-C. Bensadoun, et
al., Controlled release nanoparticle-embedded coatings reduce the tissue re-
action to neuroprostheses, J. Control. Release 145 (2010) 196e202.
[70] L.E. Haynes, M.R. Grifﬁths, R.E. Hyde, D.J. Barber, I.J. Mitchell, Dexamethasone
induces limited apoptosis and extensive sublethal damage to speciﬁc sub-
regions of the striatum and hippocampus: implications for mood disorders,
Neuroscience 104 (2001) 57e69.
[71] Y. Xie, N. Martini, C. Hassler, R.D. Kirch, T. Stieglitz, A. Seifert, et al., In vivo
monitoring of glial scar proliferation on chronically implanted neural elec-
trodes by ﬁber optical coherence tomography, Front. Neuroeng. 7 (2014) 34.
